Search
Abrilumab
go.drugbank.com/drugs/DB15076InvestigationalAbrilumab is under investigation in clinical trial NCT01290042 (Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.).
Acebilustat
go.drugbank.com/drugs/DB15385InvestigationalAcebilustat is under investigation in clinical trial NCT01748838 (Phase 1 Study Assessing the Safety and Tolerability of CTX-4430).
Nifekalant
go.drugbank.com/drugs/DB16008InvestigationalNifekalant is under investigation in clinical trial NCT03855826 (Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection).
Vantictumab
go.drugbank.com/drugs/DB12956InvestigationalVantictumab has been used in trials studying the treatment of Solid Tumors, Pancreatic Cancer, and Stage IV Pancreatic Cancer.
Eltanolone
go.drugbank.com/drugs/DB12308ExperimentalEltanolone is under investigation in clinical trial NCT02603926 (Treatment of Fragile-X Associated Tremor/Ataxia Syndrome (FXTAS) With Allopregnanolone).
KYV-101
go.drugbank.com/drugs/DB23168InvestigationalKYV-101 is under investigation in clinical trial NCT06152172 (CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101).
Rizedisben
go.drugbank.com/drugs/DB21610InvestigationalRizedisben is a small molecule drug. Rizedisben is under investigation in clinical trial NCT04983862 (Fluorescent Imaging of Nerves with Illuminare-1 During Surgery).
MaxAdFVIII
go.drugbank.com/drugs/DB17713ExperimentalMaxAdFVIII is an adenoviral vector that expresses the full-length human Factor VIII (hFVIII) cDNA. First developed by GenStar, it is being investigated for the treatment of hemophilia.
Nicotinamide Mononucleotide
go.drugbank.com/drugs/DB03227InvestigationalA nucleotide in which the nitrogenous base, nicotinamide, is in beta-N-glycosidic linkage with the C-1 position of D-ribose. Synonyms: Nicotinamide Ribonucleotide; NMN. [PubChem]
AZD-1656
go.drugbank.com/drugs/DB14810InvestigationalAZD-1656 is under investigation in clinical trial NCT00747175 (A Study to Evaluate Safety, Tolerability and P-Glucose After Multiple Ascending Oral Doses of AZD1656 in Type 2 Diabetes).